adhesion G protein-coupled receptor L4Genealiases: ELTD1 · ETL · KPG_003
Q-omics provides the consensus-scored ADGRL4 profile across patient tissues and cancer cell-line models. ADGRL4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADGRL4 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, ADGRL4 RNA expression shows 18,473 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where ADGRL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRL4 survival associations across molecular data types. ADGRL4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (13) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRL4 RNA expression–survival associations across cancer types. High ADGRL4 expression shows unfavorable associations in KIRP, UVM, MESO, STAD and BLCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ADGRL4 RNA expression.
This table summarizes ADGRL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ADGRL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRL4 shows lower tumor expression in KICH, LUSC, LUAD and KIRP and higher tumor expression in KIRC and HNSC. The KICH box plot shows higher ADGRL4 RNA expression in normal versus tumor tissue (log2 FC = −2.031, t-test p < 0.001).
This table shows molecular features associated with ADGRL4 in patient tissues and cancer cell lines. In patient samples, ADGRL4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
